| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/23/2007 | US20070197503 Solutions containing epinastin |
| 08/23/2007 | US20070197502 AMINO SUBSTITUTED DIARYL[a,d]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS |
| 08/23/2007 | US20070197501 Use Of Chemotherapeutic Agents |
| 08/23/2007 | US20070197500 3-(2,3-Dihydro-1'H-spiro[indene-1,4'-piperidin]-1'-yl)-N,N-dimethyl-2-(pyridin-2-ylmethyl)propanamide; opioid receptor-like 1 antagonist; reduced inhibitory activity at HERG potassium channel; analgesic; side effect reduction; neurpathic and other pain |
| 08/23/2007 | US20070197499 Pharmaceutical compounds |
| 08/23/2007 | US20070197498 chemical intermediate 11-((4R,6R)-4,5,6-trihydroxy-3-(R)-hydroxy-2-(S)-hydroxyhexylcarbamoyl)undecanoic acid; for making antilipemic agents; anticholesterol agents |
| 08/23/2007 | US20070197497 Compounds, compositions and methods |
| 08/23/2007 | US20070197496 for modulating cellular levels of oxidants such as superoxide radicals, hydrogen peroxide, peroxynitrite, lipid peroxides, hydroxyl radicals and thiyl radicals, treating diabetes mellitus Type I or Type II |
| 08/23/2007 | US20070197495 Anti-parasitic compounds and methods of their use |
| 08/23/2007 | US20070197494 Photosensitisers and their uses |
| 08/23/2007 | US20070197493 Selenophene anti-tumor agents |
| 08/23/2007 | US20070197491 Method for treating primary and secondary forms of glaucoma |
| 08/23/2007 | US20070197490 Method for producing 5alpha-pregnane derivative |
| 08/23/2007 | US20070197489 Composition of matter |
| 08/23/2007 | US20070197488 Prodrugs of ERbeta-selective substances, process for their production, and pharmaceutical compositions that contain these compounds |
| 08/23/2007 | US20070197487 Systems and methods for the delivery of corticosteroids having an increased lung deposition |
| 08/23/2007 | US20070197486 Methods and systems for the delivery of corticosteroids |
| 08/23/2007 | US20070197485 Therapy and Use of Compounds in Therapy |
| 08/23/2007 | US20070197484 Method of treating disorder related to high cholesterol concentration |
| 08/23/2007 | US20070197483 External preparation for treating painful skin wound |
| 08/23/2007 | US20070197482 Regulation of guanine nucleotide exchange factor for a protein belonging to the rap family of small gtpases |
| 08/23/2007 | US20070197481 to treat cellular proliferative diseases, hyperplasias, solid tumor, cardiac hypertrophy, immune disorders and inflammation; modulators of one or more mitotic kinesins; N-(2-(2-dimethylamino-acetylamino)-1-{4-[8-(1-hydroxy-ethyl)-imidazo[1,2-a]pyridin-2-yl]-benzyl}-ethyl)-3-chloro-4-isopropoxy-benzamide |
| 08/23/2007 | US20070197480 (S)-2-N-Propylamino-5-Hydroxytetralin As A D3-Agonist |
| 08/23/2007 | US20070197479 Derivatives of 4- or 5-aminosalicylic acid |
| 08/23/2007 | US20070197478 Novel pharmaceuticals |
| 08/23/2007 | US20070197477 Phosphonium salts derivatives |
| 08/23/2007 | US20070197476 Triptolide Derivatives And Their Uses |
| 08/23/2007 | US20070197475 includes rapidly excretable perfluororganic compounds e.g. perfluordecalin, perfluoractilbromide, a perfluoroganic additive embodied in the form of a mixture of perfluorinated tertiary amines contains perfluorotripropylamine and coproducts; and phospholipids in the form of a water-salt dispersion |
| 08/23/2007 | US20070197474 Methods for controlling plants pathogens using N-phosphonomethylglycine |
| 08/23/2007 | US20070197473 Methods of using SAHA and Bortezomib for treating cancer |
| 08/23/2007 | US20070197471 Treatment of degenerative cartilage conditions in a mammal with Glycosidasc Inhibitors |
| 08/23/2007 | US20070197470 Use of n-acetyl-d-aminogylcosamine in preparation of drugs for modulating microorganisms on mucous membrane |
| 08/23/2007 | US20070197469 Fluoroquinolone carboxylic acid salt compositions |
| 08/23/2007 | US20070197468 Oral formulations of cladribine |
| 08/23/2007 | US20070197467 Zafirlukast compositions |
| 08/23/2007 | US20070197466 Synthetic membrane anchors |
| 08/23/2007 | US20070197465 Hyaluronic Acid-Methotrexate Conjugate |
| 08/23/2007 | US20070197463 Antiviral nucleosides |
| 08/23/2007 | US20070197462 Administering 5-substituted uracil-nucleosides or its pharmaceutically acceptable salt or prodrug for therapy of infected with Epstein-Barr virus (EBV) or Kaposi's sarcoma-associated herpes (KHSV) |
| 08/23/2007 | US20070197461 Reducing toxicity associated with 6-mercaptopurine drug treatment via monitoring concentration of 6-thioguanine in blood; treating inflammatory bowel disease |
| 08/23/2007 | US20070197458 Nucleic acid useful for triggering tumor cell lethality |
| 08/23/2007 | US20070197457 Tak1-mediated inhibition of osteogenesis |
| 08/23/2007 | US20070197456 Preparation and diabetic use of Gibberellins |
| 08/23/2007 | US20070197454 P1-(2'-deoxycytidine 5'-)p4-(uridine 5'-)tetraphosphate, tetra-(alkali metal) salt, for treating disorders |
| 08/23/2007 | US20070197453 Compositions and methods for treatment of disorders of protein aggregation |
| 08/23/2007 | US20070197452 Treatment of amyloid-related diseases |
| 08/23/2007 | US20070197451 "street-safe" version of a controlled substance such as fentanyl, levorphanol, methadone, oxycodone, morphine, amphetamine, methylphenidate that permits the therapeutically beneficial effects while reducing euphoric effects that lead to substance abuse |
| 08/23/2007 | US20070197450 Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof |
| 08/23/2007 | US20070197449 Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof |
| 08/23/2007 | US20070197442 Methods for the Treatment of Macular Degeneration and Related Eye Conditions |
| 08/23/2007 | US20070197439 comprising glucocerebrosidase (GCB) and sucrose or trehalose in an amount sufficient to maintain the stability of the GCB, wherein the pH of the composition is less than 7.0; can be stored in liquid or lyophilized |
| 08/23/2007 | US20070197437 Compositions for enhanced epithelial permeation of y2 receptor-binding peptides |
| 08/23/2007 | US20070197427 O,o'-amidomalonate and n,o-amidomalonate platinum complexes |
| 08/23/2007 | US20070197425 comprising a thiazolidinedione, one or more of chromium picolinate or chromium polynicotinate; bioavailable source of vanadium is vanadyl sulfate; synergistic mixture |
| 08/23/2007 | US20070196931 selectively kill Fusobacterium varium cells, or neutralize the toxin produced by Fusobacterium varium cells; differential diagnosis between ulcerative colitis and inflammatory bowel disease |
| 08/23/2007 | US20070196914 Methods for preparing oil bodies comprising active ingredients |
| 08/23/2007 | US20070196908 Stabilizers For Polymerizable Biocompatible Materials |
| 08/23/2007 | US20070196885 Method of determining carbonic anhydrase i activity |
| 08/23/2007 | US20070196882 Using protein kinase C-related kinase (PRK), androgen receptor (AR) and RhoA V14 as screening tools for identifying modulators for treatment and prevention of cell proliferative and reproductive disorders |
| 08/23/2007 | US20070196866 Modulators of ion channel trpa1 |
| 08/23/2007 | US20070196859 Novel antibacterial agents |
| 08/23/2007 | US20070196856 Methods of determining activity of ryanodine receptor modulators |
| 08/23/2007 | US20070196840 Method of determining outcome of non small-cell lung cancer according to xrcc3 polymorphism |
| 08/23/2007 | US20070196524 Morinda Citrifolia Based Antifungal Formulations and Methods |
| 08/23/2007 | US20070196519 Method for making therapeutic compositions containing trimethoprim and cranberry extract for treating urinary tract infections |
| 08/23/2007 | US20070196514 Prostate cancer treatment with glycogen synthase kinase-3beta inhibitors |
| 08/23/2007 | US20070196513 Synergistic mixture of plant extract from Cissus quadrangularis and soy albumin; may include chromium, selenium,green tea extract, vitamin B6, vitamin B12 and/or folic acid; obesity, insulin resistance or diabetes; eating disorders; anticholesterol and anorexigenic agents; reduction of triglyerides |
| 08/23/2007 | US20070196512 Combinations of vanadium with antidiabetics for glucose metabolism disorders |
| 08/23/2007 | US20070196511 Nutritional composition for promoting muscle performance and acting as hydrogen (H+) blocker |
| 08/23/2007 | US20070196510 Method for treating resistant hypertension |
| 08/23/2007 | US20070196508 dietary supplement comprising mixture of taurine, andrographis paniculata, creatine pyroglutamate, creatine hydroxycitric acid salt, dipotassium phosphate, disodium phosphate or magnesium phosphate, and a source of carbohydrate |
| 08/23/2007 | US20070196506 Improved tolerance nutritional product to supplement human milk |
| 08/23/2007 | US20070196505 Compositions and Methods for Improving Skin Health and Pelage Quality |
| 08/23/2007 | US20070196501 Formulations for a tight junction effector |
| 08/23/2007 | US20070196500 Composition for oral administration of tamsulosin hydrochloride and controlled release granule formulation comprising same |
| 08/23/2007 | US20070196499 Residual Solvent extraction method and microparticles produced thereby |
| 08/23/2007 | US20070196498 Megestrol acetate suspension |
| 08/23/2007 | US20070196496 Delivery systems for functional ingredients |
| 08/23/2007 | US20070196495 Method for administering medicaments to subjects with swallowing difficulties and disorders |
| 08/23/2007 | US20070196494 Low-friability, patient-friendly orally disintegrating formulations |
| 08/23/2007 | US20070196493 Doxorubicin formulations for anti-cancer use |
| 08/23/2007 | US20070196488 Oral matrix formulations comprising licarbazepine |
| 08/23/2007 | US20070196486 Stable oral formulation containing benzimidazole derivative |
| 08/23/2007 | US20070196485 Stable benzimidazole formulation |
| 08/23/2007 | US20070196484 Poorly water-soluble drug-containing solid formulation |
| 08/23/2007 | US20070196482 a sustained release excipient ( gelling agent waxes, cellulose ether, acrylic polymer, oil, protein derived material, shellac) incorporated into a matrix along with the drug (e.g., torsemide), or applied as a controlled release coating; treatment of edema, congestive heart failure associated with edema |
| 08/23/2007 | US20070196481 Sustained-release tablet composition |
| 08/23/2007 | US20070196480 Sustained release formulation for oral administration of hmg-coa reductase inhibitor and method for the preparation thereof |
| 08/23/2007 | US20070196478 Antiviral compositions |
| 08/23/2007 | US20070196473 Pharmaceutical compositions containing flibanserin |
| 08/23/2007 | US20070196472 Phenylephrine tannate and pyrilamine tannate salts in pharmaceutical compositions |
| 08/23/2007 | US20070196471 Micronized Eplerenone Compositions |
| 08/23/2007 | US20070196470 comprising L-Arginine, Xanthinol Nicotinate, and yohimbine; bioavailability; Croscarmellose and/or Crospovidone as agents of disintegration |
| 08/23/2007 | US20070196469 Magnesium microtablets with sustained release |
| 08/23/2007 | US20070196468 Simethicone solid oral dosage form |
| 08/23/2007 | US20070196467 Indium supplement compositions and methods therefor |
| 08/23/2007 | US20070196466 Pharmaceutical formulations containing flavouring substances with improved pharmaceutical properties |
| 08/23/2007 | US20070196464 Bioavailability; absorption; using fatty acid, or salt thereof, or fatty ester |
| 08/23/2007 | US20070196463 Enteric Soft Gelatin Capsule Containing Esomerpazole And Method Of Preparation |
| 08/23/2007 | US20070196460 External preparation for treating skin or mucosal injury caused by viral infection |